Efficacy and safety of ixabepilone, a novel epothilone analogue

Clinical Breast Cancer

Volumn 7, Issue 7, 2007, Pages 543-549

  Pivot, Xavier ^a,b   Dufresne, Armelle ^a   Villanueva, Christian ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Anthracyclines; Neuropathy; Neurotoxicity; Taxanes; Toxicity

Indexed keywords

ANTIHISTAMINIC AGENT; BETA TUBULIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPOTHILONE DERIVATIVE; GEMCITABINE; IRINOTECAN; IXABEPILONE; PACLITAXEL; PLATINUM COMPLEX; PREDNISONE; TAXANE DERIVATIVE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY; IN VIVO STUDY; INFECTION; LEUKOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 34248228863     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.009     Document Type: Review

References (19)

1. Lee JJ, Swain SM. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005; 32:S22-S26.
2. Jordan MA, Miller H, Ni L, et al. The Pat-21 breast cancer model derived from a patient with primary Taxol® resistance recapitulates the phenotype of its origin, has altered β-tubulin expression and is sensitive to ixabepilone. Proc Am Assoc Cancer Res 2006; 47:21 (Abstract #LB-280).
3. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7:1429-1437.
4. Bode C, Gupta ML Jr, Rieff EA, et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilisation of yeast microtubules. Biochemistry 2002; 41:3870-3874.
5. Brooks TA, Minderman H, O'Loughlin KL, et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2003; 2:1195-1205.
6. Aghajanian C, Burris HA III, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007; 25:1082-1088.
7. Dickson N, Peck R, Wu C. Ixabepilone given weekly in patients with advanced malignancies: final efficacy and safety results of a phase I trial. J Clin Oncol 2006; 24(18 suppl):89s (Abstract #2040).
8. Denduluri N, Lee JJ, Walshe JM. Phase II clinical trial of ixabepilone in metastatic breast cancer (MBC) patients previously untreated with taxanes. J Clin Oncol 2006; 24(18 suppl):40s (Abstract #651).
9. Conte P, Thomas E, Martin M. Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): final report. J Clin Oncol 2006; 24(18 suppl):568s (Abstract #10505).
10. Thomas E, Perez EA, Mukhopadhyay P, et al. Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine. J Clin Oncol 2006; 24(18 suppl):42s (Abstract #660).
11. Pivot X, Thomas E, Lerzo G. Ixabepilone in patients with metastatic breast cancer who are resistant to an anthracycline, a taxane and capecitabine. Presented at: 31st European Society of Medical Oncology Congress; September 29-October 3, 2006; Istanbul, Turkey.
12. Llombart Cussac A, Baselga J, Manikhas G. Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast-cancer (BC): preliminary efficacy and safety data. J Clin Oncol 2005; 23(16 suppl):25s (Abstract #586).
13. Pivot X, Asmar L, Buzdar AU, et al. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 2000; 82:529-534.
14. Bunnell CA, Klimovsky J, Thomas E. Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J Clin Oncol 2006; 24(18 suppl):568s (Abstract #10511).
15. Posadas EM, Undevia S, Colevas AD, et al. A phase II study of ixabepilone (BMS 247550) in metastatic renal cell carcinoma. J Clin Oncol 2006; 24(18 suppl):648s (Abstract #14646).
16. Whitehead RP, McCoy SA, Rivkin SE, et al. A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: a Southwest Oncology Group study. J Clin Oncol 2004; 22:315 (Abstract #4012).
17. Vansteenkiste JF, Breton J-L, Sandler A, et al. A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy. J Clin Oncol 2003; 22:626 (Abstract #2519).
18. Lin AM, Rosenberg JE, Weinberg VK, et al. Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/ prednisone (MP). J Clin Oncol 2006; 24(18 suppl):231s (Abstract #4558).
19. Hussain M, Tangen CM, Lara PN Jr, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005; 23:8724-8729.